tradingkey.logo

BRIEF-Maia Biotechnology Says Lans To Initiate A Phase 3 Pivotal Trial In 2025, Named Thio-104

ReutersFeb 27, 2025 11:31 PM

- Maia Biotechnology Inc MAIA.A:

  • MAIA BIOTECHNOLOGY INC: LANS TO INITIATE A PHASE 3 PIVOTAL TRIAL IN 2025, NAMED THIO-104

  • MAIA BIOTECHNOLOGY EXPECTS TO BEGIN ENROLLING PATIENTS IN THIO-104 IN SECOND HALF OF 2025 IN SELECT COUNTRIES IN ASIA, EUROPE, U.S

Source text: [ID:n0001493152-25-008540]

Further company coverage: MAIA.A

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI